市場調查報告書
商品編碼
1466118
血漿蛋白治療市場:依產品、應用分類 - 2024-2030 年全球預測Plasma Protein Therapeutics Market by Product (Albumins, C1-esterase Inhibitors, Coagulation Factors), Application (Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder) - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
血漿蛋白治療市場規模預計2023年為325.5億美元,預計2024年將達361.9億美元,2030年將達到691.8億美元,複合年成長率為11.37%。
血漿蛋白療法由源自人類血漿的藥物組成,血漿是血液的液體成分,含有負責人類健康所需的各種功能的必需蛋白質。這些治療劑包括許多高度專業的治療方法,旨在解決因特定血漿蛋白缺乏或功能障礙而引起的各種醫療狀況。血漿蛋白療法的市場開拓涉及這些臨床用途蛋白的開發、生產和分銷。自體免疫和神經系統疾病的盛行率不斷增加,以及患者一生中定期輸液和注射的需求不斷增加,都促進了血漿蛋白治療市場的成長。血漿蛋白療法的快速取得和患者的負擔能力也推動了市場的開拓。血漿蛋白療法的副作用和有關血漿蛋白處理的嚴格規定限制了市場的成長。與血漿蛋白相關的研究和開發活動的增加表明血漿蛋白治療市場的潛在成長機會。高效蛋白血漿提取/製造流程的開拓預計將推動市場成長。
主要市場統計 | |
---|---|
基準年[2023] | 325.5億美元 |
預測年份 [2024] | 361.9億美元 |
預測年份 [2030] | 691.8億美元 |
複合年成長率(%) | 11.37% |
產品 增加使用 C1 酯酶抑制劑來控制和預防與 HAE 相關的腫脹發作
白蛋白是一種在肝臟中合成的蛋白質,負責維持血壓和運輸荷爾蒙、酵素和藥物。在治療病例中,白蛋白通常用作休克和燒傷的擴容劑,並用於治療肝功能衰竭、腎病症候群和胃腸道蛋白質流失引起的低白蛋白血症。 C1-酯酶抑制劑是調節補體系統的蛋白質,補體系統是人體免疫反應的一部分。它主要用於治療遺傳性血管性水腫(HAE)。 HAE 是一種罕見的遺傳性疾病,會導致身體各部位腫脹。凝血因子是血液凝固過程所必需的蛋白質。治療性凝血因子可預防和控制A型血友病患者的出血,血友病是一種損害凝血的遺傳性疾病。治療包括替代缺乏或缺乏的凝血因子,並且可以預防性地給予以防止出血發作或根據需要來處理急性出血。超免疫球蛋白是一種血漿來源的免疫球蛋白,含有針對特定病原體和毒素的高濃度抗體。它用於預防和治療乙型肝炎、狂犬病、破傷風和免疫力缺乏患者的某些感染疾病等疾病。免疫球蛋白(Igs)也稱為抗體,用於治療免疫力缺乏自體免疫疾病和發炎疾病、原發性和次發性免疫力缺乏以及某些感染疾病。靜脈注射靜脈注射(IVIg)和皮下靜脈注射靜脈注射(SCIg)是兩種主要製劑形式,其選擇很大程度取決於患者的偏好、耐受性和靜脈注射的可及性。血漿蛋白產品的選擇取決於具體的臨床需求。白蛋白和凝血因子分別提供重要的血漿容量和凝血功能,後者俱有許多急性使用案例,例如創傷、手術和出血控制。 C1-酯酶抑制劑和超免疫球蛋白提供針對遺傳性疾病和感染疾病的更有針對性的干涉措施。免疫球蛋白最廣泛地用作與自體免疫疾病和免疫力缺乏相關的多種疾病的治療劑。基因治療和現有治療方法適應症的擴大等最新進展導致製造業由少數積極回應醫療需求的主要企業主導。
應用擴大血漿蛋白療法在次發性於癌症和自體免疫疾病流行的免疫力缺乏疾病的應用
遺傳性血管性水腫是一種罕見的遺傳性疾病,會導致身體各部位突然、嚴重且不可預測的腫脹。 C1 酯酶抑制劑 (C1-INH) 濃縮物已用於治療 HAE,最近,重組 C1-INH 療法和激肽釋放酶抑制劑已被用作按需治療和預防。由於 HAE 發作會危及生命,因此非常需要這些治療。特發性血小板減少紫斑症是一種自體免疫疾病,會導致血小板數量低,容易造成瘀傷和出血。靜脈注射免疫靜脈注射(IVIG)可以快速提高血小板計數,常用於治療 ITP。原發性免疫力缺乏(PID) 是一組 300 多種疾病,患者身體部分免疫系統缺失或功能異常。患者通常需要終身治療,通常需要更換免疫球蛋白 (Ig)。當免疫系統受到感染疾病、化療或其他疾病等外部因素損害時,就會發生次發性免疫力缺乏(SID)。這四個應用領域的治療需求差異很大,並且取決於每種疾病的嚴重程度和慢性性質。 HAE 和 ITP 通常需要快速反應治療,而 PID 和 SID 則需要長期管理策略。
區域洞察
美洲血漿蛋白治療市場由先進的醫療基礎設施、較高的患者意識層級和主要行業參與者的存在推動,使美國成為全球主要市場之一。 FDA(美國食品藥物管理局)的法規環境確保了嚴格的品質和安全標準。在南美洲,由於醫療保健支出增加和對血漿衍生療法認知的提高,巴西和阿根廷正在成為血漿蛋白療法的主要市場。由於醫療保健意識的提高、可支配收入的增加和人口老化,亞太地區(APAC)為血漿蛋白治療市場提供了成長機會。中國和日本是該地區的重要市場,中國大力投資血漿採集和分離能力。歐洲擁有完善的醫療體系、高品質標準和優惠的報銷政策。對免疫球蛋白的需求仍然強勁,歐洲國家是血漿產品的重要出口國。在波灣合作理事會(GCC) 國家,經濟繁榮和醫療支出增加增加了對血漿蛋白治療藥物的需求。相反,儘管人們對血漿藥物的興趣不斷成長,但非洲在醫療保健基礎設施和獲得治療方面面臨重大障礙。
FPNV定位矩陣
FPNV定位矩陣對於評估血漿蛋白治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對血漿蛋白治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.血漿蛋白治療市場的市場規模與預測是多少?
2.血漿蛋白治療市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些?
3.血漿蛋白治療市場的技術趨勢和法規結構是什麼?
4.血漿蛋白治療市場主要廠商的市場佔有率是多少?
5. 進入血漿蛋白治療市場的合適型態和策略性手段是什麼?
[193 Pages Report] The Plasma Protein Therapeutics Market size was estimated at USD 32.55 billion in 2023 and expected to reach USD 36.19 billion in 2024, at a CAGR 11.37% to reach USD 69.18 billion by 2030.
Plasma protein therapeutics consist of medications derived from human plasma, the liquid component of the blood that contains essential proteins responsible for various functions necessary to human health. These therapeutics include an array of highly specialized treatments tailored to address a variety of medical conditions resulting from the absence or malfunctioning of specific plasma proteins. The market for plasma protein therapeutics includes developing, producing, and distributing these proteins for clinical use. Increased prevalence of autoimmune and neurological diseases, along with the increasing need for regular infusions or injections throughout the life of the patient, contribute to the growth of the plasma protein therapeutics market. Surging access and affordability of plasma protein therapies for patients also fuel the market development. The adverse effects of plasma protein therapeutics and strict regulations about handling plasma protein are restricting market growth. Increasing research and development activity related to the plasma protein presents a potential opportunity for growth in the plasma protein therapeutics market. The development of an efficient protein plasma extraction/manufacturing process is expected to create growth in the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 32.55 billion |
Estimated Year [2024] | USD 36.19 billion |
Forecast Year [2030] | USD 69.18 billion |
CAGR (%) | 11.37% |
Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE
Albumin, a protein synthesized by the liver, is responsible for maintaining oncotic blood pressure and transporting hormones, enzymes, and drugs. In therapeutics, albumins are often used as volume expanders in cases of shock or burns and to treat hypoalbuminemia due to liver failure, nephrotic syndrome, or gastrointestinal protein loss. C1-esterase inhibitors are proteins that regulate the complement system, which is part of the body's immune response. They are primarily used to treat hereditary angioedema (HAE), a rare genetic condition that causes swelling in various parts of the body. Coagulation factors are essential proteins in the blood clotting process. Therapeutic coagulation factors prevent and control bleeding in individuals with hemophilia A and B, which are genetic disorders that impair blood clotting. Treatments involve replacing defective or missing clotting factors, which can be administered prophylactically to prevent bleeding episodes or on-demand to manage acute bleeding. Hyperimmune globulins are plasma-derived immunoglobulins with high concentrations of antibodies targeting specific pathogens or toxins. They are used to prevent or treat diseases such as hepatitis B, rabies, tetanus, and certain types of infections in immunocompromised patients. Immunoglobulins (Ig), also known as antibodies, are used in treating a wide array of autoimmune and inflammatory diseases, primary and secondary immunodeficiencies, and certain infections. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are the two main forms offered, with the choice largely depending on patient preference, tolerability, and vein accessibility. Specific clinical needs lead to the choice among plasma protein products. Albumins and coagulation factors provide critical volume and clotting functions, respectively, often with high-urgency use cases like trauma and surgery and bleeding control for the latter. C1-esterase inhibitors and hyperimmune globulins offer more targeted interventions, focusing on genetic and infectious diseases. Immunoglobulins have the broadest application range, treating various autoimmune and immunodeficiency-related conditions. The manufacturing landscape is dominated by a few key players who robustly respond to medical needs, emphasized by recent advancements such as gene therapies and expanded indications for existing treatments.
Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases
Hereditary angioedema is a rare genetic disorder indicated by sudden, severe, and unpredictable swelling in various parts of the body. Treatment for HAE involves C1 esterase inhibitor (C1-INH) concentrates and, more recently, recombinant C1-INH therapies and kallikrein inhibitors as on-demand treatment and prevention. The need for these therapies is high, given the life-threatening nature of HAE attacks. Idiopathic thrombocytopenic purpura is an autoimmune disease that results in a low platelet count, leading to easy bruising and bleeding. Intravenous immunoglobulin (IVIG) is generally used to treat ITP, as it can quickly elevate platelet counts. Primary Immunodeficiency Disorders (PID) represent a group of over 300 disorders where part of the body's immune system is missing or functions improperly. Patients typically require lifelong therapy, often with immunoglobulin (Ig) replacement. Secondary Immunodeficiency (SID) arises when an external source such as infection, chemotherapy, or another disease impairs the immune system. The therapeutic needs across these four application segments vary significantly, with demand being shaped by both the acuteness and the chronic nature of each condition. While HAE and ITP typically require rapid response treatments, PID and SID require longer-term management strategies.
Regional Insights
The plasma protein therapeutics market in the Americas is highly developing, with the United States being one of the major global markets, driven by advanced healthcare infrastructure, high patient awareness levels, and the presence of key industry players. The regulatory environment fostered by the FDA ensures stringent quality and safety standards. In South America, Brazil and Argentina are emerging as key markets for plasma protein therapeutics due to growing healthcare expenditures and awareness about plasma-derived therapies. The Asia-Pacific (APAC) region presents a growth opportunity for the plasma protein therapeutics market, attributed to rising healthcare awareness, increasing disposable incomes, and a growing aging population. China and Japan are significant markets in this region, with China investing heavily in plasma collection and fractionation capabilities. Europe has well-established healthcare systems, high-quality standards, and favorable reimbursement policies. The need for immunoglobulins remains robust, and European countries are significant exporters of plasma products. The Gulf Cooperation Council (GCC) countries demonstrate a rising need for plasma protein therapeutics due to economic prosperity and increased healthcare spending. Conversely, Africa faces considerable hurdles in healthcare infrastructure and treatment access, although the interest in plasma-derived medicinal products is growing.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Plasma Protein Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Plasma Protein Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Access Biologicals LLC, ADMA Biologics, Inc., AmerisourceBergen Corporation, Baxter International Inc., Bio Products Laboratory Ltd., Bruker Corporation, China Biologic Products Holdings, Inc., CSL Limited, DiaPharma, Emergent BioSolutions, FFF Enterprises, Inc., GC Biopharma corp, Grifols, S.A., Hemarus Therapeutics Limited, KalVista Pharmaceuticals, Kamada Ltd., Kedrion S.p.A., Laboratory Corporation of America Holdings, LFB SA, Octapharma AG, Plasma Technologies, LLC, PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Plasma Protein Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Plasma Protein Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Plasma Protein Therapeutics Market?
4. What is the market share of the leading vendors in the Plasma Protein Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Plasma Protein Therapeutics Market?